Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Huidan Zhang, Dongju Han, Tongtong Lv, Kehang Liu, Yunqing Yang, Xixi Xu & Yuqing Chen. (2019) Novel peptide myristoly-CM4 induces selective cytotoxicity in leukemia K562/MDR and Jurkat cells by necrosis and/or apoptosis pathway. Drug Design, Development and Therapy 13, pages 2153-2167.
Read now
Read now
Articles from other publishers (19)
Yang-Yang Gao, Wei-Cheng Yang, Charles R. AshbyJr.Jr. & Ge-Fei Hao. (2023) Mapping cryptic binding sites of drug targets to overcome drug resistance. Drug Resistance Updates 67, pages 100934.
Crossref
Crossref
Surya K. De. (2023) Asciminib: first FDA approved allosteric inhibitor of BCR-ABL1 for the treatment of chronic myeloid leukemia. Medicinal Chemistry Research 32:3, pages 424-433.
Crossref
Crossref
Mingxing Teng, Marlise R. Luskin, Sandra W. Cowan-Jacob, Qiang Ding, Doriano Fabbro & Nathanael S. Gray. (2022) The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug. Journal of Medicinal Chemistry 65:11, pages 7581-7594.
Crossref
Crossref
Zhi-Zheng Wang, Xing-Xing Shi, Guang-Yi Huang, Ge-Fei Hao & Guang-Fu Yang. (2021) Fragment-based drug design facilitates selective kinase inhibitor discovery. Trends in Pharmacological Sciences 42:7, pages 551-565.
Crossref
Crossref
Ahmed A. El Rashedy, Patrick Appiah-Kubi & Mahmoud E. S. Soliman. (2019) A Synergistic Combination Against Chronic Myeloid Leukemia: An Intra-molecular Mechanism of Communication in BCR–ABL1 Resistance. The Protein Journal 38:2, pages 142-150.
Crossref
Crossref
Elisabetta Abruzzese, Paolo de Fabritiis, Malgorzata M. Trawinska, Pasquale Niscola, Jane F. Apperley & Michael J. Mauro. (2018) Back to the future: Treatment‐free remission and pregnancy in chronic myeloid leukemia. European Journal of Haematology 102:2, pages 197-199.
Crossref
Crossref
Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, Silvia Buonamici, Simona Cotesta, Sandra W. Cowan-Jacob, Stephanie Dodd, Peter Drueckes, Doriano Fabbro, Tobias Gabriel, Jean-Marc Groell, Robert M. Grotzfeld, A. Quamrul Hassan, Chrystèle Henry, Varsha Iyer, Darryl Jones, Franco Lombardo, Alice Loo, Paul W. Manley, Xavier Pellé, Gabriele Rummel, Bahaa Salem, Markus Warmuth, Andrew A. Wylie, Thomas Zoller, Andreas L. Marzinzik & Pascal Furet. (2018) Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. Journal of Medicinal Chemistry 61:18, pages 8120-8135.
Crossref
Crossref
Josephine T. Tauer, Bernadette A. S. Jäger, Anna Ulmer, Paula Geidel, Vera Girke, Lysann Kroschwald & Meinolf Suttorp. 2018. Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy. Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy.
Martin C. Müller, Francisco Cervantes, Henrik Hjorth-Hansen, Jeroen J.W.M. Janssen, Dragana Milojkovic, Delphine Rea & Gianantonio Rosti. (2017) Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel. Critical Reviews in Oncology/Hematology 120, pages 52-59.
Crossref
Crossref
Lukasz Skora & Wolfgang Jahnke. (2017)
19
F-NMR-Based Dual-Site Reporter Assay for the Discovery and Distinction of Catalytic and Allosteric Kinase Inhibitors
. ACS Medicinal Chemistry Letters 8:6, pages 632-635.
Crossref
Crossref
Pierre Laneuville. (2017) Stopping second-generation TKIs in CML. Blood 129:7, pages 805-806.
Crossref
Crossref
Raushan T. Kurmasheva & Peter J. Houghton. 2017. Patient-Derived Mouse Models of Cancer. Patient-Derived Mouse Models of Cancer
133
159
.
Paul W. Manley & Nikolaus J. Stiefl. 2018. Cancer II. Cancer II
1
37
.
Hae Ryung Chang, Hee Seo Park, Young Zoo Ahn, Seungyoon Nam, Hae Rim Jung, Sungjin Park, Sang Jin Lee, Curt Balch, Garth Powis, Ja-Lok Ku & Yon Hui Kim. (2016) Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems. BMC Cancer 16:1.
Crossref
Crossref
Giovanna Carrà, Davide Torti, Sabrina Crivellaro, Cristina Panuzzo, Riccardo Taulli, Daniela Cilloni, Angelo Guerrasio, Giuseppe Saglio & Alessandro Morotti. (2016) The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias. Oncotarget 7:40, pages 66287-66298.
Crossref
Crossref
Chie Nishioka, Takayuki Ikezoe, Jing Yang & Akihito Yokoyama. (2016) BCR/ABL increases EZH2 levels which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia cells. Leukemia Research 45, pages 24-32.
Crossref
Crossref
Elise C. Kohn & S. Percy Ivy. (2016) Confronting the Care Delivery Challenges Arising from Precision Medicine. Frontiers in Oncology 6.
Crossref
Crossref
Fiorenzo Santoleri, Ruggero Lasala, Elena Ranucci, Gaetano La Barba, Roberto Di Lorenzo, Antonio Vetrò, Paolo Di Bartolomeo & Alberto Costantini. (2016) Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response. Acta Haematologica 136:1, pages 45-51.
Crossref
Crossref
Mahmoud Toulany & H. Peter Rodemann. (2015) Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation. Seminars in Cancer Biology 35, pages 180-190.
Crossref
Crossref